Tuesday November 24 2009 | Biotechnology feed | All feeds
|
|
Tuesday November 24 2009 | Biotechnology feed | All feeds
|
|
|
Ezetimibe prevents the development of artherosclerosis In the USA, dietary cholesterol and saturated fatty acid intake is high significantly increases the risk of coronary artery disease. Since a staggering 12.4 million Americans suffer coronary artery disease identifying new hypolipidemic strategies is of vital importance. The high incidence of hyperlipidemia has created a market worth $15.9 billion world-wide and this has stimulated considerable pharmaceutical activity and consequently 182 molecules are in various stages of development or on the market. 43% of these are in preclinical development suggesting that interest in this field is stable and hence the search for new candidates continues. Schering-Plough's Ezetimibe, represents the first selective inhibitor of intestinal cholesterol absorption. Cholesterol absorption has been shown to be inhibited by >90% at doses of ezetimibe >3 mg/kg in apoE-/- mice which represent a model of atherosclerosis. These animals fed a western diet develop aortic atherosclerotic lesions which are reduced by 80% following drug treatment. Similarly, carotid artery atherosclerotic lesion cross-sectional area was reduced by 97%. This data confirm that Ezetimibe is able to reduce cholesterol levels and for the first time shows, crucially that it can reduce the development of atherosclerosis. Projects such as these are overviewed in full DiscoveryDossiers. DiscoveryDossiers ~ TherapeuticsAdvances ~ PharmaceuticalSolutions ~ LeadDiscovery ~ Purchase DiscoveryDossiersLeadDiscovery and BioPortfolio aims to provide reliable, insightful analysis on the biotechnology industry. However, this information is provided "as is" and no representations or warranties either express or implied of completeness, accuracy, or of any other nature are made with respect to this information. This information is neither an offer to sell nor a solicitation to buy the securities of any company. This information contains forward-looking statements, which involve risks and uncertainties which may not be listed. The biotechnology industry is an emerging industry and the securities of the companies mentioned in this report have a very high degree of risk and volatility. For this reason, this information is supplied on the condition that the reader will make his or her own determination as to its suitability for any purpose prior to any use of this information. The employees and officers of LeadDiscovery and BioPortfolio may hold positions in some or all of the stocks discussed in this report. This abstract has been produced by LeadDiscovery Ltd. Founded by life scientists for life scientists we aim to help industry identify cutting edge drug discovery options and academic/biotech institutions maximize the potential of their research. Abstracts strictly reflect the opinion of LeadDiscovery's editorial panel. While all reasonable efforts are made to ensure the accuracy of information provided LeadDiscovery and the publisher BioPortfolio, takes no responsibility for incorrect or misleading information. LeadDiscovery is designed for educational and drug development purposes only and is not intended or designed to offer medical advice or advice of any sort, and must not be used for such purpose. The information provided through LeadDiscovery and BioPortfolio should not be used for diagnosing or treating a health problem or a disease and no reliance should be placed on any information contained in this abstract or elsewhere on LeadDiscovery's and BioPortfolio's website. It is not intended to be a substitute for professional care. If you have or suspect you may have a health problem, you should consult your physician or other health care provider.
|
|
|
